110 related articles for article (PubMed ID: 20717823)
21. Nuclear Receptor Imaging In Vivo-Clinical and Research Advances.
Parent EE; Fowler AM
J Endocr Soc; 2023 Jan; 7(3):bvac197. PubMed ID: 36655003
[TBL] [Abstract][Full Text] [Related]
22. PET Imaging of Estrogen Receptors Using
Kumar M; Salem K; Jeffery JJ; Fowler AM
Methods Mol Biol; 2022; 2418():129-151. PubMed ID: 35119664
[TBL] [Abstract][Full Text] [Related]
23. Preclinical Applications of Multi-Platform Imaging in Animal Models of Cancer.
Serkova NJ; Glunde K; Haney CR; Farhoud M; De Lille A; Redente EF; Simberg D; Westerly DC; Griffin L; Mason RP
Cancer Res; 2021 Mar; 81(5):1189-1200. PubMed ID: 33262127
[TBL] [Abstract][Full Text] [Related]
24. Quick Automatic Synthesis of Solvent-Free 16α-[
Jiang X; Li Y; Wang X; Shen T; Li X; Yao Y; Zhang G; Kou Y; Shen J; Luo Z; Cheng Z
Front Oncol; 2020; 10():577979. PubMed ID: 33102235
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of 16α-
Yamada S; Tsuyoshi H; Yamamoto M; Tsujikawa T; Kiyono Y; Okazawa H; Yoshida Y
J Nucl Med; 2021 May; 62(5):636-642. PubMed ID: 33008930
[TBL] [Abstract][Full Text] [Related]
26. Imaging of Preclinical Endometrial Cancer Models for Monitoring Tumor Progression and Response to Targeted Therapy.
Espedal H; Fonnes T; Fasmer KE; Krakstad C; Haldorsen IS
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31783595
[TBL] [Abstract][Full Text] [Related]
27. A review on immunohistochemical and histopathologic validation in PET-CT findings with consideration to microRNAs.
Bădan MI; Bonci EA; Piciu D
Med Pharm Rep; 2019 Oct; 92(4):337-345. PubMed ID: 31750432
[TBL] [Abstract][Full Text] [Related]
28. Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review.
van Weelden WJ; Massuger LFAG; ; Pijnenborg JMA; Romano A
Front Oncol; 2019; 9():359. PubMed ID: 31134155
[No Abstract] [Full Text] [Related]
29. Linked Hexokinase and Glucose-6-Phosphatase Activities Reflect Grade of Ovarian Malignancy.
Olsen BB; Gjedde A; Vilstrup MH; Johnsen IBG; Neumann G; Torigian DA; Alavi A; Høilund-Carlsen PF
Mol Imaging Biol; 2019 Apr; 21(2):375-381. PubMed ID: 29987620
[TBL] [Abstract][Full Text] [Related]
30. What's New in Imaging for Gynecologic Cancer?
Khan SR; Arshad M; Wallitt K; Stewart V; Bharwani N; Barwick TD
Curr Oncol Rep; 2017 Nov; 19(12):85. PubMed ID: 29105030
[TBL] [Abstract][Full Text] [Related]
31. Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer
Paquette M; Lavallée É; Phoenix S; Ouellet R; Senta H; van Lier JE; Guérin B; Lecomte R; Turcotte ÉE
J Nucl Med; 2018 Feb; 59(2):197-203. PubMed ID: 28798032
[TBL] [Abstract][Full Text] [Related]
32. Correlation between the Uptake of 18F-Fluorodeoxyglucose (18F-FDG) and the Expression of Proliferation-Associated Antigen Ki-67 in Cancer Patients: A Meta-Analysis.
Deng SM; Zhang W; Zhang B; Chen YY; Li JH; Wu YW
PLoS One; 2015; 10(6):e0129028. PubMed ID: 26038827
[TBL] [Abstract][Full Text] [Related]
33. Radiopharmaceuticals as probes to characterize tumour tissue.
Alam IS; Arshad MA; Nguyen QD; Aboagye EO
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(4):537-61. PubMed ID: 25647074
[TBL] [Abstract][Full Text] [Related]
34. Efficient acid-catalyzed (18) F/(19) F fluoride exchange of BODIPY dyes.
Keliher EJ; Klubnick JA; Reiner T; Mazitschek R; Weissleder R
ChemMedChem; 2014 Jul; 9(7):1368-73. PubMed ID: 24596307
[TBL] [Abstract][Full Text] [Related]
35. Assessment of the novel estrogen receptor PET tracer 4-fluoro-11β-methoxy-16α-[(18)F]fluoroestradiol (4FMFES) by PET imaging in a breast cancer murine model.
Paquette M; Phoenix S; Ouellet R; Langlois R; van Lier JE; Turcotte EE; Bénard F; Lecomte R
Mol Imaging Biol; 2013 Oct; 15(5):625-32. PubMed ID: 23619898
[TBL] [Abstract][Full Text] [Related]
36. Oestrogen-related tumour phenotype: positron emission tomography characterisation with ¹⁸F-FDG and ¹⁸F-FES.
Tsujikawa T; Yoshida Y; Maeda H; Tsuchida T; Mori T; Kiyono Y; Kimura H; Okazawa H
Br J Radiol; 2012 Jul; 85(1015):1020-4. PubMed ID: 22337690
[TBL] [Abstract][Full Text] [Related]
37. Additional value of 16α-[18F]fluoro-17β-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on [18F]fluorodeoxyglucose PET.
Yoshida Y; Kiyono Y; Tsujikawa T; Kurokawa T; Okazawa H; Kotsuji F
Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1824-31. PubMed ID: 21656049
[TBL] [Abstract][Full Text] [Related]
38. Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[¹⁸F]fluoro-17β-oestradiol PET.
Tsujikawa T; Yoshida Y; Kiyono Y; Kurokawa T; Kudo T; Fujibayashi Y; Kotsuji F; Okazawa H
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):37-45. PubMed ID: 20717823
[TBL] [Abstract][Full Text] [Related]
39. Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET.
Tsujikawa T; Yoshida Y; Kudo T; Kiyono Y; Kurokawa T; Kobayashi M; Tsuchida T; Fujibayashi Y; Kotsuji F; Okazawa H
J Nucl Med; 2009 Oct; 50(10):1598-604. PubMed ID: 19759112
[TBL] [Abstract][Full Text] [Related]
40. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.
Zhao Z; Yoshida Y; Kurokawa T; Kiyono Y; Mori T; Okazawa H
J Nucl Med; 2013 Apr; 54(4):499-506. PubMed ID: 23471314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
